Intellect Deal With Japanese Firm Could Accelerate Company's Alzheimer's Programs
This article was originally published in PharmAsia News
Executive Summary
A reciprocal licensing deal with Japanese reagent and diagnostics firm Immuno-Biological Laboratories will allow Intellect Neurosciences to move its passive immunotherapy for Alzheimer's disease to the clinic faster. Read more